3 Domestic Pharmaceuticals Company, Software Services Company and Aluminium and Copper Maker Stocks With a Strong Future Roadmap: Mankind Pharma, Sonata Software and Hindalco Industries
- November 13, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Mankind Pharma, Sonata Software and Hindalco Industries: ROE of 11.7% to 26.7% and FY22 to FY26 revenue CAGR of 9.1% to 17.6%. Prices as of 12 Nov 2026.
Quick Answer
The three pharma, software and aluminium stocks to watch are Mankind Pharma, Sonata Software and Hindalco Industries. Their return on equity ranges from 11.7% to 26.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.1% to 17.6%. Sonata Software leads on both return on equity at 26.7% and revenue growth at 17.6% a year. Prices are based on the 12 November 2026 close, and this article is educational, not investment advice.
Pharma, software and aluminium stocks let investors follow companies that serve a growing part of the Indian economy. Mankind Pharma, Sonata Software and Hindalco Industries cover a domestic pharmaceuticals company, a software services company and an aluminium and copper maker.
This list covers three pharma, software and aluminium stocks with complete current figures: Mankind Pharma, Sonata Software and Hindalco Industries. Every figure comes from the latest reported financials and the 12 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pharma, Software and Aluminium Stocks?
Pharma, software and aluminium stocks are listed companies that sell branded medicines and consumer health products across India, build software platforms and services for global clients, and make aluminium, copper and value added metal products. Their earnings depend on medicine demand, client technology budgets and metal prices.
Pharma, Software and Aluminium Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Mankind Pharma | 2,638.6 | 93,014 | 45.0 | 36.0 | 11.7 | 0.39 |
| Sonata Software | 257.13 | 6,732 | 14.5 | 17.5 | 26.7 | 0.38 |
| Hindalco Industries | 964 | 202,250 | 12.3 | 11.6 | 12.8 | 0.73 |
On valuation, Sonata Software trades at a P/E below the industry P/E, while Mankind Pharma and Hindalco Industries trade above it, which reflects the growth the market already expects. Readers comparing pharma, software and aluminium stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in pharma, software and aluminium stocks can use the coming numbers to test whether growth is holding.
Why Do Pharma, Software and Aluminium Stocks Have a Strong Roadmap in India?
Pharma, software and aluminium stocks have a strong roadmap in India because growing access to medicines, rising spending on technology platforms and strong demand for aluminium in power and vehicles keep widening the market for these companies.
- Pharmaceuticals. Families buy trusted branded medicines.
- Software services. Global firms build digital platforms.
- Aluminium and copper. Power and vehicles need more metal.
Why Mankind Pharma Features Among These Pharma, Software and Aluminium Stocks
Among the pharma, software and aluminium stocks on this list, Mankind Pharma is one of India’s largest pharmaceutical companies by domestic sales, with a strong presence in chronic and acute therapies, consumer healthcare brands and a large field force.
The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0.
Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore.
Roadmap: The company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.
What to watch: Watch the market share in chronic therapies and the integration of acquired brands.
Why Sonata Software Features Among These Pharma, Software and Aluminium Stocks
Among the branded medicines, product engineering and copper shares on this list, Sonata Software, based in Bengaluru, is a technology services company with a focus on the Microsoft ecosystem and a platform-led approach it calls modernisation.
Revenue rose from Rs 5,655 crore in FY22 to Rs 10,806 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 376 crore in FY22 to Rs 464 crore in FY26, which works out to a compound annual growth rate of 5.4%.
In the June 2026 quarter, revenue grew 9.9% year on year to Rs 3,286 crore. The company has a return on equity of 26.7%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 6,732 crore. The stock trades at a P/E of 14.5, below the industry P/E of 17.5.
Roadmap: Its strategy centres on cloud, data and artificial intelligence projects for retail, travel and manufacturing clients. A strong partner relationship with Microsoft and a pipeline of large deals support its roadmap.
What to watch: Monitor deal wins and trends in the domestic business.
Why Hindalco Industries Features Among These Pharma, Software and Aluminium Stocks
Among the three companies on this list, Hindalco Industries is a metals leader with aluminium, copper and speciality alumina businesses, and it owns Novelis, one of the world’s largest aluminium rolling and recycling companies.
In the June 2026 quarter, revenue grew 32.5% year on year to Rs 85,882 crore, while net profit rose 75.1% to Rs 7,013 crore. Revenue rose from Rs 196,195 crore in FY22 to Rs 277,833 crore in FY26, a compound annual growth rate of 9.1%.
Net profit grew from Rs 10,097 crore in FY23 to Rs 13,391 crore in FY26, which works out to a compound annual growth rate of 9.9%. The company has a return on equity of 12.8%, a debt to equity ratio of 0.73 and a market capitalisation of Rs 202,250 crore. The stock trades at a P/E of 12.3, above the industry P/E of 11.6.
Roadmap: The company is investing in aluminium downstream products, copper and battery foil, and Novelis is expanding capacity for beverage cans and automotive aluminium. A mix of upstream and downstream operations spreads exposure across the aluminium chain.
What to watch: Monitor aluminium and copper price trends and the progress of its major capex projects.
Mankind Pharma vs Sonata Software vs Hindalco Industries on Key Financials
The table below sets the three pharma, software and aluminium stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Mankind Pharma | 7,978 | 14,636 | 16.4% | 1,938 | 13.2% |
| Sonata Software | 5,655 | 10,806 | 17.6% | 464 | 4.3% |
| Hindalco Industries | 196,195 | 277,833 | 9.1% | 13,391 | 4.8% |
Sonata Software posts the highest return on equity in this group at 26.7%. Hindalco Industries has the largest FY26 revenue at Rs 277,833 crore, and Sonata Software shows the fastest revenue growth with a 17.6% compound annual rate. A useful habit with pharma, software and aluminium stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Mankind Pharma | 3,650 | 4,076 | 11.7% |
| Sonata Software | 2,989 | 3,286 | 9.9% |
| Hindalco Industries | 64,834 | 85,882 | 32.5% |
Key Risks to Check Before Investing in Pharma, Software and Aluminium Stocks
Every theme carries risks that deserve a check before any decision. For these pharma, software and aluminium stocks, the main points are: Long-term branded medicines, product engineering and copper shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Currency moves. Export earnings move with the rupee.
- Commodity prices. Selling prices follow global and domestic markets.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pharma, software and aluminium stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pharma, Software and Aluminium Stocks
Pharma, software and aluminium stocks reward investors who follow demand trends, order books and margins together. Mankind Pharma, Sonata Software and Hindalco Industries each have a clear plan to grow. Based on the 12 November 2026 close, Mankind Pharma trades at Rs 2,638.6, Sonata Software at Rs 257.13 and Hindalco Industries at Rs 964. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these pharma, software and aluminium stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track pharma, software and aluminium stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pharma, software and aluminium stocks?
Ans. Pharma, software and aluminium stocks are listed companies that sell branded medicines and consumer health products across India, build software platforms and services for global clients, and make aluminium, copper and value added metal products. Their earnings depend on medicine demand, client technology budgets and metal prices. This list looks at three of them, Mankind Pharma, Sonata Software and Hindalco Industries, using reported FY22 to FY26 financials and the 12 November 2026 closing prices.
Which pharma, software and aluminium stocks are covered in this list?
Ans. This list covers Mankind Pharma, Sonata Software and Hindalco Industries. Based on the 12 November 2026 close, Mankind Pharma traded at Rs 2,638.6, Sonata Software at Rs 257.13 and Hindalco Industries at Rs 964. Their return on equity ranges from 11.7% to 26.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.1% to 17.6%.
Why do pharma, software and aluminium stocks have a strong future roadmap in India?
Ans. Pharma, software and aluminium stocks have a strong roadmap in India because growing access to medicines, rising spending on technology platforms and strong demand for aluminium in power and vehicles keep widening the market for these companies. The main drivers are as follows. Pharmaceuticals. Families buy trusted branded medicines. Software services. Global firms build digital platforms. Aluminium and copper. Power and vehicles need more metal. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Mankind Pharma performed financially?
Ans. Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0. Looking ahead, the company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.
How has Sonata Software performed financially?
Ans. Revenue rose from Rs 5,655 crore in FY22 to Rs 10,806 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 376 crore in FY22 to Rs 464 crore in FY26, which works out to a compound annual growth rate of 5.4%. In the June 2026 quarter, revenue grew 9.9% year on year to Rs 3,286 crore. The company has a return on equity of 26.7%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 6,732 crore. The stock trades at a P/E of 14.5, below the industry P/E of 17.5. Looking ahead, its strategy centres on cloud, data and artificial intelligence projects for retail, travel and manufacturing clients. A strong partner relationship with Microsoft and a pipeline of large deals support its roadmap.
How has Hindalco Industries performed financially?
Ans. Revenue rose from Rs 196,195 crore in FY22 to Rs 277,833 crore in FY26, a compound annual growth rate of 9.1%. Net profit grew from Rs 10,097 crore in FY23 to Rs 13,391 crore in FY26, which works out to a compound annual growth rate of 9.9%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 85,882 crore, while net profit rose 75.1% to Rs 7,013 crore. The company has a return on equity of 12.8%, a debt to equity ratio of 0.73 and a market capitalisation of Rs 202,250 crore. The stock trades at a P/E of 12.3, above the industry P/E of 11.6. Looking ahead, the company is investing in aluminium downstream products, copper and battery foil, and Novelis is expanding capacity for beverage cans and automotive aluminium. A mix of upstream and downstream operations spreads exposure across the aluminium chain.
What risks should investors check before buying pharma, software and aluminium stocks?
Ans. Investors should check a few risks before buying pharma, software and aluminium stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Commodity prices. Selling prices follow global and domestic markets. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pharma, software and aluminium stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 12 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
